A Phase 2 Study of Zongertinib in People With HER2-Positive Advanced Solid Tumors

Full Title

Beamion PANTUMOR-1: A Phase II, Multicentre, Multicohort, Open-Label Trial to Evaluate the Efficacy and Safety of Oral Zongertinib (BI 1810631) for the Treatment of Selected HER2 Mutated or Overexpressed/Amplified Solid Tumours

Purpose

Researchers want to see if zongertinib is safe and works well to treat advanced solid tumors. The people in this study have solid tumors that metastasized (spread). The tumors contain an abnormal HER2 protein (mutation) or too much HER2 (overexpression/amplification). HER2 promotes the growth of cancer cells.

Zongertinib blocks the HER2 protein and may help slow or stop the growth of your cancer. Researchers think zongertinib may work better and cause fewer or milder side effects than other HER2-blocking therapies. Zongertinib is taken orally (by mouth).

Who Can Join

To join this study, there are a few conditions. You must:

• Have a metastatic solid tumor with HER2 overexpression/amplification or mutation which cannot be cured with existing treatments.
• Have recovered from the serious side effects of prior therapies before taking zongertinib.
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 or older.

Contact

For more information or to see if you can join this study, please call Dr. Alison Schram’s office at  646-888-5388.